Equity Research: Moderna Inc. (MRNA)
1. Cover Block
Company / Ticker / Exchange: Moderna Inc. / MRNA / NASDAQ
Report Date: December 8, 2025
Last Close: $27.73 | Fair-Value Estimate: $36.00 | Price/FVE: 0.77 | Market Cap: $10.8 Billion
Economic Moat: None | Uncertainty Rating: Very High | Capital Allocation Rating: Standard
Equity Style Box: Mid-Cap Growth | Sector: Healthcare | Industry: Biotechnology | ESG Risk Rating: Low (19.2)
2. Contents
Cover Block
Contents
Analyst Note
Business Description
Business Strategy & Outlook
Bulls Say / Bears Say
Economic Moat
Fair Value and Profit Drivers
Risk & Uncertainty
Capital Allocation
Financials Snapshot
ESG Risk
Appendix
Sources
3. Analyst Note
Moderna Inc. (MRNA) stands at a defining precipice in the fourth quarter of 2025, executing a painful but necessary strategic metamorphosis from a pandemic-era growth phenomenon to a disciplined, multi-product commercial biotechnology company. The company’s trajectory throughout 2025 has been characterized by significant volatility, culminating in a third-quarter performance that beat tempered expectations but underscored the harsh realities of a contracting core market and a high-risk developmental pipeline. As of December 8, 2025, the stock trades at approximately $27.73, down significantly from its 52-week high of $48.92, reflecting a market that has largely repriced the equity to exclude the premium once assigned to its platform optionality.
In the third quarter of 2025, Moderna reported revenue of $1.02 billion, surpassing analyst consensus of roughly $860 million. This beat was driven primarily by the earlier-than-anticipated timing of U.S. COVID-19 vaccine approvals and subsequent stocking, rather than a fundamental expansion of demand. Despite this ephemeral upside, the broader financial narrative remains one of contraction: total revenue declined roughly 45% year-over-year compared to Q3 2024, driven by the continued endemic erosion of Spikevax volumes. Consequently, management has narrowed its full-year 2025 revenue guidance to a range of $1.6 billion to $2.0 billion, a reduction at the top end that signals limited incremental upside for the remainder of the fiscal year.
The most consequential updates, however, concern the pipeline and cost structure. The failure of the Phase 3 CMVictory trial for the cytomegalovirus (CMV) vaccine (mRNA-1647) to meet its primary efficacy endpoint was a material blow to the company’s "latent virus" thesis. This failure necessitated the discontinuation of the program, removing a potential blockbuster revenue stream previously modeled for 2026/2027. In response to this and other headwinds, management has aggressively pivoted toward capital preservation, committing to reducing R&D expenses by $1.1 billion starting in 2027 and aiming for cash flow breakeven by 2028. This "right-sizing" includes the discontinuation of several other assets, including the HSV (mRNA-1608) and VZV (mRNA-1468) programs.
While the "Standard" Capital Allocation rating reflects a fortified balance sheet with $6.6 billion in cash and investments , the "None" Economic Moat rating and "Very High" Uncertainty rating remain appropriate. The bullish thesis now rests almost entirely on the success of the individualized neoantigen therapy (INT), mRNA-4157, currently in Phase 3 trials for melanoma and non-small cell lung cancer (NSCLC). With accelerated approval off the table, the regulatory timeline has lengthened, testing investor patience. We maintain a Fair Value Estimate of $36.00, implying the stock is undervalued, but caution that this valuation is contingent on successful execution in oncology and the stabilization of the respiratory franchise.
4. Business Description
Moderna Inc. is a commercial-stage biotechnology company based in Cambridge, Massachusetts, that has pioneered the development of messenger RNA (mRNA) therapeutics and vaccines. The company’s proprietary platform is designed to direct the body's cellular machinery to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit. This approach conceptualizes mRNA as "software"—a genetic code that can be rapidly engineered and manufactured—potentially allowing for faster development timelines and higher success rates compared to traditional small-molecule or biologic drug development.
Key Technology and Mechanism
At the core of Moderna's business is its Lipid Nanoparticle (LNP) delivery system. mRNA is inherently unstable and easily degraded by the body's enzymes. Moderna’s IP portfolio focuses heavily on the chemical formulation of LNPs that encapsulate the mRNA, protecting it until it can enter target cells. Once inside, the mRNA instructs the ribosome to manufacture a specific protein (e.g., the Spike protein of SARS-CoV-2 or a tumor-specific neoantigen), which then triggers an immune response. This technology platform is modular; the same manufacturing processes can theoretically be used to produce vaccines for influenza, cancer therapies, or protein replacement therapies for rare diseases.
Operating Segments and Commercial Portfolio
Moderna operates as a single reportable segment but manages its portfolio across several therapeutic modalities:
Commercial Respiratory Vaccines:
Spikevax (COVID-19): The company’s flagship commercial product. It targets the SARS-CoV-2 virus and has been updated seasonally to address emerging variants. Sales are now highly seasonal, concentrated in the third and fourth quarters of the calendar year.
mRESVIA (RSV): An mRNA-based vaccine for Respiratory Syncytial Virus (RSV) approved for adults aged 60 and older. Launched in 2024, it competes directly with protein-based vaccines from GSK (Arexvy) and Pfizer (Abrysvo). Commercial uptake has been disappointing, with Q3 2025 sales of only $2 million, indicating significant challenges in market penetration.
Developmental Pipeline:
Oncology (INT): The Individualized Neoantigen Therapy (INT) program, led by mRNA-4157 (V940), creates personalized cancer vaccines based on the unique mutational signature of a patient's tumor. This is developed in a 50/50 profit-sharing partnership with Merck.
Latent and Public Health Vaccines: This area has seen significant consolidation. Following the failure of the CMV candidate and the discontinuation of HSV and VZV programs, the focus has narrowed to the Norovirus vaccine (mRNA-1403) and Epstein-Barr Virus (EBV) candidates.
Rare Diseases: The company is advancing therapeutics for Propionic Acidemia (mRNA-3927) and Methylmalonic Acidemia (mRNA-3705), aiming to restore missing enzymes in patients with genetic disorders.
Geographies and Manufacturing
Moderna generates the majority of its revenue in the United States, which accounted for approximately $1.2 billion of the $1.8 billion in Spikevax sales reported in Q3 2024 (comparative data point for geographic split). The company has invested heavily in establishing a global manufacturing footprint, including the onshoring of drug product capabilities in the U.S. to reduce reliance on contract manufacturing organizations (CMOs) and improve gross margins. International commercial operations are managed through subsidiaries in Europe, Canada, Japan, and Australia, though the U.S. remains the primary profit driver.
5. Business Strategy & Outlook
Strategic Pivot: From Pandemic Expansion to Commercial Discipline
Moderna’s overarching strategy for the 2025-2028 period is defined by a rigorous prioritization of capital toward assets with the highest probability of success and the largest commercial potential. The "growth at any cost" phase fueled by the pandemic cash windfall has ended. The new strategic imperative is to achieve cash flow breakeven by 2028 without diluting shareholders. This involves a "three-pillar" approach:
Defend and Stabilize Respiratory Revenue: The company aims to maintain its share of the COVID-19 market while launching next-generation combination vaccines. The Flu+COVID combination (mRNA-1083) is viewed as a critical product to combat "vaccine fatigue" and offer convenience, potentially commanding a premium price and stabilizing volumes. However, regulatory delays mean this product will not contribute to revenue until at least 2026 .
Deliver on Oncology: With the decline of the latent virus portfolio, the oncology franchise has become the primary growth engine. Moderna is aggressively investing in the Phase 3 trials for mRNA-4157 in melanoma and NSCLC. The strategy relies on demonstrating that INT can serve as a foundational adjuvant therapy alongside checkpoint inhibitors like Keytruda.
Drive Operational Efficiency: The company is executing a $1.1 billion reduction in annual R&D spending starting in 2027. This includes halting early-stage exploratory programs and focusing manufacturing resources on onshoring to drive gross margins toward a long-term target of 75-80%.
Competitive Edge
Moderna’s competitive edge, traditionally defined by the speed of its platform, is evolving. In the respiratory market, speed allows for better matching of vaccines to circulating strains, a critical advantage in influenza and COVID-19. However, the commercial failure of mRESVIA suggests that speed and efficacy alone are insufficient against entrenched incumbents with superior commercial infrastructure and contracting leverage. In oncology, the competitive advantage lies in the proprietary bioinformatics algorithm and rapid manufacturing turnaround time (vein-to-vein time) required for personalized therapies—a complex logistical moat that competitors may find difficult to replicate at scale.
Secular Trends
The broader biopharmaceutical landscape is shifting away from pure pandemic response toward the management of endemic respiratory diseases and the treatment of complex conditions like cancer through immunotherapy. Secular trends favoring Moderna include the increasing prevalence of cancer survivorship creating a larger adjuvant therapy market, and the aging global population driving demand for adult vaccines (RSV, Flu, Shingles). Conversely, "vaccine fatigue" and politicized public health sentiment in the U.S. present significant headwinds to uptake rates for respiratory products.
Medium-Term View (2025-2028)
We view the period from late 2025 through 2027 as a "Valley of Death" for Moderna. Revenue is expected to trough in 2025 ($1.6–$2.0 billion) and remain constrained in 2026 as the Flu+COVID combo ramps up and mRESVIA struggles for relevance. Significant revenue growth is unlikely to resume until 2027/2028, contingent on the launch of the Norovirus vaccine and the first oncology indications. The company’s ability to manage its $6.6 billion cash pile during these lean years is the single most critical factor for equity performance. The updated guidance to end 2025 with $6.5–$7.0 billion in cash (up from $6 billion previously) is a positive signal of disciplined execution.
6. Bulls Say / Bears Say
Bulls Say:
Oncology Paradigm Shift: The Phase 2 data for mRNA-4157 in adjuvant melanoma demonstrated a 49% reduction in the risk of recurrence or death compared to Keytruda alone. If replicated in Phase 3, this establishes a new standard of care in a multi-billion dollar market. The extension into NSCLC and other solid tumors could unlock a Total Addressable Market (TAM) exceeding $30 billion.
Fortress Balance Sheet: Ending Q3 2025 with $6.6 billion in cash and investments, plus a $1.5 billion credit facility, Moderna has the liquidity to withstand years of losses without diluting shareholders. This financial resilience is rare for a biotech of its size .
Norovirus Opportunity: The Norovirus vaccine (mRNA-1403) targets a virus with no approved vaccine and a significant burden of disease (leading cause of acute gastroenteritis). With Phase 3 trials underway, this represents a largely de-risked "blue ocean" commercial opportunity that competitors are not addressing .
Operational Discipline: Management’s decisive action to cut $1.1 billion in R&D and discontinue low-probability programs (CMV, HSV, VZV) demonstrates a commitment to shareholder value over scientific curiosity. The upward revision of year-end cash guidance is proof that these measures are working.
Bears Say:
Broken Commercial Model: The catastrophic commercial underperformance of mRESVIA ($2 million in Q3 sales vs. blockbuster expectations) proves that Moderna lacks the commercial muscle to compete with Pfizer and GSK in non-pandemic markets. Without a partner, they may fail to monetize even successful pipeline assets.
Pipeline Attrition: The failure of the CMV vaccine (mRNA-1647) is a devastating blow to the platform’s credibility beyond COVID. It was supposed to be the "sure thing" latent virus vaccine. Its failure casts doubt on the entire non-respiratory infectious disease portfolio.
Valuation Disconnect: Despite the stock drop, MRNA trades at roughly 5-6x 2025 revenue, a premium valuation that assumes successful oncology execution. If mRNA-4157 fails Phase 3, the stock has no floor, as the respiratory franchise alone cannot support the current market cap.
Litigation Overhang: The ongoing patent war with Arbutus Biopharma regarding LNP delivery systems threatens the company’s freedom to operate. An unfavorable ruling in the upcoming March 2026 trial could result in massive damages and ongoing royalty burdens that would severely compress future margins .
7. Economic Moat
We assign Moderna a None Economic Moat rating. While the company was a pioneer in commercializing mRNA technology, the structural dynamics of the industry and the company’s current financial profile do not support the existence of a durable competitive advantage that would guarantee returns on invested capital (ROIC) above the weighted average cost of capital (WACC) for the next 10-20 years.
Absence of Switching Costs
The vaccine market, particularly for respiratory illnesses, is characterized by low switching costs for the end-user. Patients and providers view COVID-19 and Flu vaccines as largely interchangeable commodities. This was starkly evident in the RSV market launch in 2024/2025, where Moderna’s mRESVIA—despite being the only mRNA option—failed to displace GSK’s Arexvy or Pfizer’s Abrysvo. The company’s inability to lock in customers or command a price premium in a competitive market undermines the "switching cost" moat source.
Intangible Assets: Under Siege
Moderna’s intellectual property (IP) portfolio, once considered its strongest asset, is currently under significant legal duress. The company is defending multiple patent infringement lawsuits from Arbutus Biopharma and Genevant Sciences regarding the lipid nanoparticles (LNPs) used to deliver mRNA. In favorable rulings for Arbutus, courts have validated claims that could force Moderna to pay royalties on past and future sales. Furthermore, the rapid entry of BioNTech/Pfizer and now other competitors like CureVac (partnered with GSK) into the mRNA space demonstrates that the technology, while difficult, is not exclusive to Moderna.
Cost Advantage: Not Yet Realized
While the mRNA platform theoretically offers speed and cost advantages in development, Moderna’s current financial reality contradicts a cost-advantage moat. The company reported a net loss of $200 million in Q3 2025 and gross margins that are pressured by lower volumes and write-offs. The company is currently "right-sizing" its manufacturing footprint, but until it achieves high capacity utilization across multiple commercial products, it suffers from negative operating leverage.
Quantitative Evidence
A durable moat is quantitatively evidenced by sustained ROIC > WACC. Moderna’s ROIC was spectacular during the pandemic (128% in 2021) but has since turned deeply negative (-20.6% in 2023, -25.4% TTM 2025) . The forecasted ROIC remains below our estimated WACC of 9.5% through at least 2028. Without a structural advantage generating excess returns in a normalized environment, a moat cannot be assigned.
8. Fair Value and Profit Drivers
We estimate a Fair Value for Moderna Inc. of $36.00 per share. This valuation implies a price-to-sales multiple of approximately 3.6x on our 2027 revenue estimate and reflects a weighted probability assessment of the oncology pipeline.
Revenue Growth & Drivers
Our financial model assumes the following trajectory:
2025 Revenue: We model $1.8 billion, the midpoint of management's updated guidance ($1.6B–$2.0B). This is comprised almost entirely of Spikevax sales, with negligible contribution from mRESVIA.
2026 Revenue: We project a slight recovery to $2.0 billion. This assumes the launch of the Flu+COVID combination vaccine (mRNA-1083) in the second half of the year, contributing ~$200 million, while standalone COVID sales continue to decline. We model mRESVIA sales remaining flat at ~$50 million due to entrenched competition.
2027 Revenue: We forecast a jump to $2.8 billion. This is the inflection point in our model, driven by:
Oncology (INT): We assign a 60% Probability of Success (POS) to the approval of mRNA-4157 in adjuvant melanoma. We model a launch in late 2026/early 2027 with initial year sales of $500 million (Moderna’s 50% share of gross profit recognized as revenue/profit share).
Norovirus: We assign a 50% POS to the Norovirus vaccine (mRNA-1403), launching in 2027 with $300 million in sales, targeting the institutional (cruise ships, military, nursing homes) market.
Terminal Growth: We assume a 2.5% terminal growth rate post-2029, consistent with mature pharmaceutical industry trends.
Profitability & Margins
Gross Margin: We project gross margins to improve from the current ~60-62% range to 76% by 2029. This expansion is driven by the onshoring of manufacturing (eliminating CMO margins) and the shift in product mix toward higher-margin oncology therapeutics.
R&D Expenses: We aggressively model the $1.1 billion cut in R&D. We forecast R&D expense dropping from ~$4.8 billion in 2024 to ~$3.6 billion in 2027. This is the primary driver of our projected return to profitability.
Operating Margin: We project operating margins to remain negative through 2027, crossing into positive territory (approx. 2.0%) in 2028 as the oncology revenue ramps and cost cuts fully materialize.
Discount Rate (WACC)
We utilize a Weighted Average Cost of Capital (WACC) of 9.5%. This is at the higher end of the mature biopharma range (typically 7-9%) but lower than early-stage biotech (12-15%). This reflects the dichotomy of Moderna’s risk profile: it has the balance sheet of a major pharma but the earnings volatility of a clinical-stage biotech. The "Very High" uncertainty rating necessitates this risk premium .
Valuation Implication
At $27.73, the stock trades at a ~23% discount to our Fair Value. This discount suggests the market is pricing in a failure of the oncology pipeline or a significantly lower peak sales potential for the respiratory franchise than we model.
9. Risk & Uncertainty
We assign Moderna a Very High Uncertainty Rating. The distribution of potential outcomes for shareholders is exceptionally wide, ranging from a multi-product oncology leader to a shrinking single-product vaccine manufacturer.
Clinical & Pipeline Risk
This is the most acute risk. The failure of the CMV vaccine (mRNA-1647) demonstrated that Phase 2 success does not guarantee Phase 3 data. The company’s valuation is now heavily levered to the success of mRNA-4157 in oncology. Oncology trials are notoriously risky; while Phase 2b data was strong, the Phase 3 trials in melanoma and NSCLC are powered for recurrence-free survival and overall survival, endpoints that take years to mature. A failure here would remove the primary growth driver from the model.
Regulatory Risk
The regulatory environment has become more challenging. The FDA has shown a willingness to delay approvals and demand more data, as seen with the Flu+COVID combination vaccine delays. Furthermore, the political landscape in the U.S. presents a unique risk; the appointment of vaccine-skeptical leadership at the Department of Health and Human Services (HHS) could lead to reduced federal funding for mRNA research, narrower vaccine recommendations from the CDC/ACIP, or increased scrutiny on safety signals, all of which would dampen commercial uptake.
Commercial & Competitive Risk
Moderna faces execution risk in commercialization. The mRESVIA launch failure highlights the difficulty of competing against "Big Pharma" marketing machines. In the combination vaccine market, Moderna will face direct competition from Pfizer/BioNTech and Novavax/Sanofi. In oncology, mRNA-4157 will compete with other neoantigen approaches and bispecific antibodies.
Legal Risk (Patent Litigation)
The patent dispute with Arbutus Biopharma and Genevant Sciences is a critical overhang. The U.S. trial is scheduled for March 2026. If Moderna loses, it could be liable for damages on historical COVID vaccine sales (potentially >$1 billion) and be forced to pay royalties on future LNP-based products. This would directly impact the net present value of every asset in the pipeline .
Macroeconomic Risk
While Moderna has a strong cash position, a prolonged high-interest-rate environment increases the cost of capital for the sector and compresses valuation multiples. Additionally, as a global company, Moderna is exposed to foreign exchange risk, which negatively impacted its cash position in 2024.
10. Capital Allocation
We rate Moderna’s Capital Allocation as Standard.
Balance Sheet Strength
Moderna maintains a robust balance sheet, a legacy of its pandemic success. As of the end of Q3 2025, the company held $6.6 billion in cash, cash equivalents, and investments. Additionally, the company secured a $1.5 billion revolving credit facility with Ares Management in November 2025, providing further liquidity insurance. This capital buffer is sufficient to fund the company’s operations through its projected breakeven point in 2028, assuming the cost-cutting plan is executed faithfully.
Investment Strategy & Discipline
Management’s investment track record is mixed. The aggressive expansion of the pipeline into 15+ concurrent programs during 2021-2023 led to a bloated cost structure that is now being painfully unwound. The $1.1 billion reduction in R&D and the discontinuation of the HSV, VZV, and CMV programs reflect a return to discipline, but the capital consumed by these failed/halted programs represents significant value destruction. However, the investment in onshoring manufacturing capabilities is a strategically sound move that creates long-term structural margin benefits. The partnership with Merck for INT is also a prudent allocation decision, as it shares the substantial costs and risks of oncology development while leveraging Merck’s commercial expertise with Keytruda.
Shareholder Distributions
Moderna does not pay a dividend and suspended its share repurchase program in 2024 to preserve capital. Given the negative free cash flow profile and the high cost of capital for its pipeline investments, this is the correct allocation decision. We do not anticipate any return of capital to shareholders until at least 2029, after the company has achieved sustained profitability.
11. Financials Snapshot
Table 1: Moderna Inc. Financial Forecast (2022–2029)
Metric
FY 2022 (A)
FY 2023 (A)
FY 2024 (A)
FY 2025 (E)
FY 2026 (E)
FY 2027 (E)
FY 2028 (E)
FY 2029 (E)
Revenue ($B)
19.3
6.8
3.2
1.8
2.0
2.8
3.5
4.2
Growth (%)
4.3%
-64.4%
-52.7%
-43.8%
11.1%
40.0%
25.0%
20.0%
Op. Margin (%)
45.0%
-45.0%
-110%
-290%
-150%
-40%
2.0%
15.0%
EPS ($)
20.12
-12.33
-9.28
-8.12
-7.00
-2.50
0.50
2.10
FCF ($B)
4.6
-3.8
-4.1
-3.2
-2.5
-1.2
0.2
0.9
ROIC (%)
45.8%
-20.6%
-25.4%
-38.8%
-30.0%
-15.0%
2.0%
8.5%

Source: Historicals from Company Filings . Estimates based on Analyst Model derived from guidance .
Commentary on Financials:
The forecast illustrates the "Valley of Death." 2025 represents the revenue trough. The EPS recovery trails revenue growth due to the fixed nature of manufacturing costs and the gradual phase-in of R&D cuts. We project positive Free Cash Flow (FCF) only in 2028, coinciding with the maturation of the oncology franchise and the normalization of Capex.
12. ESG Risk
Sustainalytics ESG Risk Rating: Low (19.2)
Moderna maintains a favorable ESG profile, primarily driven by the societal value of its product portfolio and its governance structures.
Access to Healthcare (Social)
As a developer of vaccines for global pandemics and neglected diseases (like Norovirus), Moderna scores highly on the social dimension. The company has committed to tiered pricing models to ensure access in low-and-middle-income countries (LMICs) and continues to partner with organizations like IAVI for HIV vaccine development. However, pricing disputes in Europe and the U.S. regarding the commercial price of Spikevax (~$130/dose) have created some reputational friction.
Human Capital (Social)
The recent strategic restructuring involving layoffs and program cancellations presents a risk to human capital management. Retaining top scientific talent in a "shrinking" organization is challenging. While the company has been named a "Top Employer" by Science for 11 years, employee morale metrics will be a key watch item going forward.
Product Governance (Social)
Safety and quality are paramount. The company incurred approximately $0.2 billion in non-cash charges related to manufacturing resizing in 2024/2025. While there have been no major safety scandals, the high scrutiny on mRNA vaccines means any adverse event (like the single GBS case in the Norovirus trial that caused a temporary hold) can have outsized stock impacts.
Carbon Footprint (Environmental)
Moderna is recognized as a "Low Carbon Leader" relative to the broader industrial sector. Its manufacturing processes are generally less resource-intensive than traditional biologics (mammalian cell culture), leading to a smaller energy and water footprint per dose.
13. Appendix
Key Valuation Assumptions Table
Parameter
Value
Rationale
Risk-Free Rate
4.2%
Based on current 10-Year US Treasury yield estimates.
Equity Risk Premium
5.5%
Standard market risk premium.
Beta
1.11
Reflects high historical volatility and correlation to biotech sector.
Cost of Equity
10.3%
Calculated via CAPM (4.2% + 1.11 * 5.5%).
Cost of Debt
6.5%
Estimated based on recent credit facility terms and credit rating.
WACC
9.5%
Weighted average of equity and debt costs; aligns with biotech peers .
Terminal Growth Rate
2.5%
Aligns with long-term healthcare inflation and GDP growth.
INT Prob. of Success
60%
Adjusted for Phase 2 data strength but Phase 3 regulatory hurdles.
Norovirus POS
50%
Standard Phase 3 probability for infectious disease vaccines.

Glossary of Ratings:
Economic Moat: A structural advantage that protects profits from competition (Wide, Narrow, None).
Uncertainty Rating: Assessing the predictability of future cash flows (Low, Medium, High, Very High).
Fair Value Estimate: The analyst's calculation of the intrinsic value of the share price based on DCF modeling.
14. Sources
Zacks Investment Research. "Moderna stock price market cap beta December 8 2025". Zacks.com. December 8, 2025.
Google Finance. "Moderna stock price market cap beta December 8 2025". December 8, 2025.
Moderna Inc. "Stock Info". investors.modernatx.com. December 5, 2025.
Investing.com. "Moderna (MRNA) Trading Status". December 7, 2025.
Moderna Inc. "Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates". investors.modernatx.com. November 6, 2025.
Investing.com. "Earnings call transcript: Moderna's Q3 2025 earnings beat expectations". November 6, 2025.
Moderna Inc. "Moderna Reports Third Quarter 2024 Financial Results". November 7, 2024.
Moderna Inc. "Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities". November 19, 2025.
Moderna Inc. "Events & Presentations". investors.modernatx.com.
Moderna Inc. "2024 Financial Summary". Moderna Q4 Earnings Presentation.
Issuer Direct. "Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results". February 2025.
Macrotrends. "Moderna Revenue 2021-2025". macrotrends.net.
Moderna Inc. "Consolidated Statements of Cash Flows". 2024 Annual Report.
Moderna Inc. "Annual Reports". investors.modernatx.com.
StockStory. "MRNA Q3 Deep Dive: Cost Controls and Pipeline Progress". November 7, 2025.
Zacks Investment Research. "Moderna Q3 Earnings Beat, Stock Up on Revised Spending Plans". November 6, 2025.
Investing.com. "Moderna Q3 2025 slides: Cost discipline offsets revenue decline". November 6, 2025.
BioPharma Dive. "Moderna 3Q 2025 earnings: Vaccine sales cost cuts". November 6, 2025.
Moderna Inc. "News and Blog Posts". news.modernatx.com.
Fintel. "Moderna analyst consensus revenue estimates 2025 2026". fintel.io.
Zacks Investment Research. "Detailed Earning Estimates". zacks.com.
Nasdaq. "Moderna Yearly Earnings Forecast". nasdaq.com.
Simply Wall St. "Moderna Future Growth". simplywall.st. December 3, 2025.
Nasdaq. "Moderna Stock Analyst Estimates & Ratings". nasdaq.com.
PharmiWeb. "Moderna Reports Third Quarter 2025 Financial Results". November 6, 2025.
BioPharma Dive. "Moderna mRESVIA Q3 2025 sales revenue". November 6, 2025.
WebDisclosure. "Moderna Reports $1 Billion Revenue in Q3 2025".
Investing.com. "Moderna Q3 2025 Financial Comparison".
ASCO. "Abstract 440346: mRNA-4157 Phase 3 melanoma trial status". asco.org.
Moderna Inc. "Product Pipeline". modernatx.com. November 21, 2025.
Merck & Co. "Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940". merck.com.
Moderna Inc. "mRNA-4157-P201 Trial". trials.modernatx.com.
Oncology Pipeline. "Another bump in Moderna's neoantigen road". October 13, 2025.
Moderna Inc. "Research Product Pipeline". modernatx.com. November 21, 2025.
PMC. "RNA-based cancer vaccines". pmc.ncbi.nlm.nih.gov.
Merck & Co. "Phase 3 Trial Evaluating Adjuvant V940 in NSCLC". merck.com.
Oncology Pipeline. "Moderna mRNA-4157 non-small cell lung cancer trial progress". October 13, 2025.
ASCO Pubs. "TPS8116 Background". ascopubs.org.
Clinical Trials Arena. "Moderna scraps mRNA vaccine in congenital CMV on Phase III failure". October 23, 2025.
PharmExec. "Moderna ceases development mRNA-1647". October 22, 2025.
National CMV Foundation. "Update on Moderna's CMV Vaccine Trial Results". October 22, 2025.
Moderna Inc. "mRNA-1647-P301 Trial". trials.modernatx.com.
Moderna Inc. "Reflecting on Moderna's Phase 3 CMV Vaccine Readout". October 22, 2025.
Fierce Biotech. "Moderna's norovirus Phase 3 study heads north again". November 2025.
Promega Connections. "Norovirus Vaccine Development".
Contagion Live. "FDA places hold on Moderna's norovirus vaccine".
Vax Before Travel. "Guillain-Barré syndrome risk identified norovirus vaccine candidate". February 17, 2025.
Moderna Inc. "mRNA-1403-P301 Trial". trials.modernatx.com.
Nasdaq. "Moderna consensus revenue EPS estimates". nasdaq.com.
Fintel. "Moderna Projected Revenue". fintel.io.
Zacks. "Detailed Earning Estimates". zacks.com.
Moderna Inc. "Quarterly Results". investors.modernatx.com.
Nasdaq. "Moderna Stock Analyst Estimates". nasdaq.com.
SEC.gov. "Exhibit 99.1 Moderna Reports Third Quarter 2025".
WebDisclosure. "Moderna Reports Revenue Q3 2025".
BioPharma Dive. "Moderna reported only $2 million in mResvia sales". November 6, 2025.
Investing.com. "Moderna's COVID product portfolio".
PharmiWeb. "Moderna Analyst Day Highlights Pipeline Progress". November 20, 2025.
Moderna Inc. "2025 Analyst Day Presentation". November 20, 2025.
Seeking Alpha. "Moderna Inc. (MRNA) Analyst/Investor Day Transcript". November 20, 2025.
Moderna Inc. "Analyst Day 2025 Recap".
Moderna Inc. "Events & Presentations Overview".
Investing.com. "Moderna outlines growth strategy".
Fierce Pharma. "Moderna takes $1.5B loan".
BioSpace. "Moderna slashes R&D budget by $1.1B".
Issuer Direct. "Moderna 2026-2028 outlook".
Contract Pharma. "Moderna Cuts R&D Spending, Focuses on Oncology". September 13, 2024.
Morningstar. "Moderna Sustainalytics ESG Risk Rating". September 3, 2025.
Sustainalytics. "Low Carbon Leaders".
Sustainalytics. "ESG Data".
MSCI. "ESG Ratings".
Sustainalytics. "ESG Research".
BioPharma Dive. "Moderna guidance 2025 JPM shares fall". January 13, 2025.
Investing.com. "Moderna sees Q2 2025 revenue drop".
Simply Wall St. "Future Growth Analysis". December 3, 2025.
Fintel. "Moderna Analyst Downgrades".
Investopedia. "Moderna gets analyst downgrade".
Chartmill. "Moderna Reports Q3 2025 Revenue Beat".
Moderna Inc. "Q3 2025 Report".
Morningstar. "Moderna Reports Third Quarter 2025 Financial Results". November 6, 2025.
Moderna Inc. "Analyst Day 2025 Video".
Moderna Inc. "Analyst Coverage".
BioPharma Dive. "BioNTech stock performance vs Moderna". November 6, 2025.
Danelfin. "BNTX vs MRNA Stock Comparison".
JUVE Patent. "Arbutus and Brinkhof celebrate success in mRNA case against Moderna". May 28, 2025.
IPWatchdog. "mRNA Patent Wars Update". March 23, 2025.
Arbutus Biopharma. "Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement".
Arbutus Biopharma. "Legal Proceedings File".
Markman Advisors. "Will Moderna Prevail Against Arbutus". September 5, 2025.
Macrotrends. "Moderna Free Cash Flow 2022-2025".
Zacks. "Cash Flow Statements".
Moderna Inc. "Quarterly Results Downloads".
Investing.com. "Moderna Cash Flow".
AlphaSpread. "Moderna Return on Invested Capital".
Trefis. "Moderna ROIC Data".
ROIC.ai. "Moderna ROIC Quote".
Chartmill. "Moderna Fundamental Analysis".
Markets.com. "Trending Stock Analysis: Moderna".
Trefis. "Why Moderna Stock Is Crumbling". June 9, 2025.
BioSpace. "Analysts Tell Moderna Investors to Hold".
Danelfin. "BNTX vs MRNA AI Score".
Danelfin. "MRNA vs BNTX AI Score".
BioNTech SE. "BioNTech Announces Third Quarter 2025 Results".
BioNTech SE. "BioNTech Present Progress Oncology Pipeline". May 27, 2025.
BioNTech SE. "Pipeline and Products".
BioNTech SE. "Clinical Pipeline PDF". August 28, 2025.
Quiver Quant. "Arbutus Biopharma Reports Q3 2025 Results".
IPWatchdog. "mRNA Patent Wars Update".
JUVE Patent. "Arbutus Success in mRNA Case". May 28, 2025.
Unified Patent Court. "Order C9E23...".
Markman Advisors. "Moderna 1498 Defense".
KPMG. "Cost of Capital Parameters 2025".
Phoenix Strategy Group. "Cost of Capital Industry Benchmarks".
NYU Stern. "Cost of Equity and Capital (US) - Biotechnology". January 2025.
Finrofca. "Biotech Revenue Multiples 2025".
Ropes & Gray. "Life Sciences Industry 2024 and What's Next". February 2025.
Finbox. "Moderna Return on Invested Capital".
Trefis. "Moderna Data Companies".
Macrotrends. "Moderna ROI".
Moderna Inc. "Historical Stock Quote".
Disclaimer: This analysis is for informational purposes only and is not a recommendation to buy or sell any security.
